I wrote last week about how nothing is going right in the Fosamax cases. Now, something went right. A jury in New York yesterday awarded $285,000 to a plaintiff for Novartis on the defective design case. Which is fine, really. You only need one reason to win.
Is $285,000 a huge victory in a piece of litigation where some injuries are so utterly awful? No. But after a string of losses, a win is a win. Could this be the turning of the tide in these cases? I think Novartis will probably bet no, and keep on trying these cases. We will see.